Conceptus, Inc. is in the process of getting approval for its STOP (TM) contraceptive procedure. The market for a non-surgical method of permanent contraception is huge (over 800,000 procedures a year) and STOP has many cost and convenience advantages over the current procedure of tubal litigation.
Today, Conceptus announced the private placement of 1.94 million shares. The cash generated from this financing will allow Conceptus to fund its trials for STOP.
Currently, there are no analysts following the stock and and it appears to be off the radar screen for most investors. The potential for this company is incredible and I believe it is worth consideration by those who can tolerate the high risk/reward ratio of this stock. |
